仅供教育参考，不构成投资建议
基因编辑的经济学
这个行业如何融资、资金的实际用途，以及临床成功为何如此难以预测。
上市公司
Atlas中已上市的基因编辑公司。我们不提供实时市场数据——市值等数字时刻变化，因此我们为您链接至一手来源，而非展示一个您读到时已过时的数字。
| 企业 | 股票代码 | 交流 | 总部 | 平台 | 当前阶段 |
|---|---|---|---|---|---|
| CRISPR Therapeutics | CRSP | Nasdaq | Zug, Switzerland | CRISPR-Cas9 platform | Approved |
| Intellia Therapeutics | NTLA | Nasdaq | Cambridge, Massachusetts | In vivo CRISPR platform | Phase III |
| Beam Therapeutics | BEAM | Nasdaq | Cambridge, Massachusetts | Base editing platform | Phase III |
| Editas Medicine | EDIT | Nasdaq | Cambridge, Massachusetts | In vivo editing | Preclinical |
| Prime Medicine | PRME | Nasdaq | Cambridge, Massachusetts | Prime editing platform | Phase I/II |
| Caribou Biosciences | CRBU | Nasdaq | Berkeley, California | Cell therapy | Phase I |
| Sana Biotechnology | SANA | Nasdaq | Seattle, Washington | Cell engineering | Phase I |
| Vertex Pharmaceuticals | VRTX | Nasdaq | Boston, Massachusetts | Large biotechnology | Approved |
| Sangamo Therapeutics | SGMO | Nasdaq | Richmond, California | Zinc finger platform | Phase III |
| Eli Lilly and Company | LLY | NYSE | Indianapolis, Indiana | Large pharmaceutical | Phase II |
私营企业
风险投资支持或私人持有。融资数据来自各公司官方公告，每份档案均注明日期。
Boston, Massachusetts
Verve Therapeutics
Built to turn heart disease into a one-time treatment, and acquired by Eli Lilly in 2025…
已融资: Acquired by Eli Lilly for ~$1 billion plus CVR
Alameda, California
Scribe Therapeutics
Co-founded by Jennifer Doudna to engineer CRISPR enzymes from scratch rather than use the…
Brisbane, California
Mammoth Biosciences
Co-founded by Jennifer Doudna around ultra-compact CRISPR proteins small enough to fit…
Cambridge, Massachusetts
Arbor Biotechnologies
Co-founded by Feng Zhang and David Scott to discover new editing enzymes from nature at…
Somerville, Massachusetts
bluebird bio
A pioneer of lentiviral gene addition with several approved therapies — and a cautionary…
Somerville, Massachusetts
Tessera Therapeutics
Developing 'gene writing' — mobile genetic elements repurposed to insert whole sequences…
Durham, North Carolina
Tune Therapeutics
Turning genes up and down without changing sequence — epigenetic editing taken into early…
行业列表
了解经济学背景
为什么一次性治愈在商业上很困难、优先审评资格证书的价值几何，以及基因疗法的定价逻辑。
企业、融资与交易动态
来自指定出版商；每条标题均链接至原文。
在哪里获取我们未收录的数据
公司文件
对于在美上市公司，SEC EDGAR系统收录了年度报告（10-K）和季度报告（10-Q），包含现金状况和运营支出——这是评估一家尚未盈利的生物科技公司最关键的两项数据。